Table 3.
Relationship between immunoreactivity scores of SOX7, SOX9, SOX10 and clinicopathological features of PCa
| Clinical features (Numbers) |
SOX7 |
SOX9 |
SOX10 |
|||
|---|---|---|---|---|---|---|
|
IRS |
P
|
IRS |
P
|
IRS |
P
|
|
| X̅ ± s | X̅ ± s | X̅ ± s | ||||
| Age (years) | ||||||
| < 70 (75) |
3.93 ± 0.219 |
0.530 |
7.46 ± 0.268 |
0.114 |
2.73 ± 0.215 |
0.875 |
| ≥70 (72) |
4.14 ± 0.224 |
6.68 ± 0.403 |
2.79 ± 0.295 |
|||
| Serum PSA Levels (ng/ml) | ||||||
| <4 (27) |
4.50 ± 0.330 |
0.021 |
7.17 ± 0.560 |
0.968 |
3.29 ± 0.456 |
0.025 |
| ≥4 (120) |
3.34 ± 0.183 |
7.14 ± 0.251 |
2.33 ± 0.185 |
|||
| Gleason Score | ||||||
| < 8 (118) |
4.09 ± 0.183 |
0.317 |
5.93 ± 0.606 |
0.024 |
2.66 ± 0.188 |
0.276 |
| ≥8 (29) |
3.69 ± 0.322 |
7.46 ± 0.235 |
3.14 ± 0.438 |
|||
| Clinical Stage | ||||||
| <T2A(79) |
3.95 ± 0.205 |
0.431 |
6.39 ± 0.326 |
<0.001 |
2.62 ± 0.226 |
0.498 |
| ≥T2A(68) |
4.21 ± 0.259 |
8.25 ± 0.270 |
2.86 ± 0.269 |
|||
| Pathological Stage | ||||||
| T2A-T2C(86) |
4.06 ± 0.209 |
0.742 |
7.23 ± 0.282 |
0.693 |
3.53 ± 0.214 |
0.013 |
| T3A-T4(61) |
3.95 ± 0.249 |
7.05 ± 0.381 |
2.27 ± 0.287 |
|||
| Metstasis | ||||||
| No (119) |
4.88 ± 0.179 |
0.025 |
7.34 ± 0.240 |
0.104 |
2.67 ± 0.186 |
0.327 |
| Yes (28) | 3.75 ± 0.359 | 6.39 ± 0.611 | 3.11 ± 0.455 | |||